COO — The Cooper Companies, Inc.

Summary of Cooper Companies Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Consolidated Revenues: $1.065 billion, up 4.6% year-over-year (3.4% organic growth).
• Operating Income: Increased 9% to a 27% margin.
• Non-GAAP EPS: Grew 11% to $1.15.
• Free Cash Flow: Strong at $150 million, with a total of nearly $300 million for fiscal 2025.
• Share Repurchases: Nearly $200 million in Q4, totaling about $300 million for the fiscal year, with a new $2 billion repurchase plan authorized.

2. Strategic Updates and Business Highlights

• CooperVision: Focused on market share gains through the MyDay premium daily silicone hydrogel lens portfolio. Strong momentum in private label contracts and upcoming product launches expected to drive revenue growth.
• CooperSurgical: Revenue of $356 million, up 4% year-over-year. Notable growth in the fertility segment, with optimism for stronger performance in fiscal 2026.
• Reorganization Efforts: Completed significant integration work aimed at improving operational efficiency, resulting in expected annual pretax savings of approximately $50 million starting in fiscal 2026.
• Strategic Review: A formal review initiated to explore options for unlocking long-term shareholder value, including potential separation of CooperVision and CooperSurgical.

3. Forward Guidance and Outlook

• Fiscal Q1 2026 Guidance: Consolidated revenues expected between $1.019 billion and $1.03 billion (3% to 4% organic growth).
• Full Year 2026 Guidance: Consolidated revenues projected at $4.3 billion to $4.34 billion (4.5% to 5.5% organic growth). Non-GAAP EPS expected between $4.45 and $4.60.
• Free Cash Flow: Projected to improve to $575 million to $625 million in fiscal 2026, with a long-term target of over $2.2 billion from 2026 to 2028.

4. Bad News, Challenges, or Points of Concern

• Market Weakness: Notable softness in China, particularly in low-margin e-commerce channels, with a 28% decline in Q4. This weakness is not expected to significantly impact overall profitability.
• Gross Margin Pressure: Margins are expected to decline due to tariffs and product mix, particularly as daily silicone hydrogel lenses grow, which have lower margins compared to older products.
• Competitive Pressures: Concerns about pricing power in the contact lens market, with expectations of only 1% global pricing growth.

5. Notable Q&A Insights

• Clarity Product Line: Revenue for Clarity is declining, approaching $400 million annually. Management is repositioning this product line, particularly in Asia Pac, to target entry-level markets.
• Strategic Review: The review is ongoing, with no immediate plans for separation, but management is open to exploring options that could enhance shareholder value.
• Private Label Opportunities: New contracts in the U.S. and Europe are expected to contribute positively in fiscal 2026, with management optimistic about upcoming launches.
• Fertility Segment: Despite current softness, there are signs of recovery in the U.S. market, and management is cautiously optimistic about growth in fiscal 2026.

This summary encapsulates the key financial metrics, strategic initiatives, future guidance, and challenges faced by Cooper Companies as discussed in the Q4 2025 earnings call.